STING1 and head and neck squamous cell carcinoma: This phase 0 study employing the CIVO microdosing platform with spatial profiling and IHC assessments evaluated the immune response changes induced by the STING agonist dazostinag alone and in combination with widely employed chemotherapies within the TME of patients with HNSCC.